



2026 Solid Tumor Rules

Presented by: Melissa Riddle, ODS-C

Iowa Cancer Registry

Recorded December 2025

1

1

Download the 2026 STR

- Solid Tumor Rules should be used as soon as they are released
 - Don't wait for a specific diagnosis year
- The latest STR should be downloaded:
 - <https://seer.cancer.gov/tools/solidtumor/>
- Full listing of changes can be found here:
 - <https://seer.cancer.gov/tools/solidtumor/revisions.html>

Solid Tumor Rules
2026 Update (view Revision History)

[Download the Solid Tumor Rules 2026 Update \(PDF, 8.7 MB\) \(December 12, 2025\)](#)

Purpose of Solid Tumor Rules

The purpose of the Solid Tumor Rules is to determine the number of primaries to abstract and the histology to code. **The most recent Solid Tumor Rules update should be used as soon as it is released** and can be applied to 2018+ cases (see General Instructions for start years for each Site-group). If a specific code or instruction has an effective year later than 2018, it will be noted in the text.

2026 Solid Tumor Rules Release Announcement

The Solid Tumor Rules have been updated for 2026. In addition to the standard annual updates, the Solid Tumor Manual underwent a substantial reformulating to improve clarity and usability.

Key updates include the following:

- Restructured general instructions
- Reformatted and restructured the Histology tables
 - Changed from 3 columns to 2 columns
 - Histology corrections made in several site-group tables
 - In table notes moved to footnotes
- Malignant and Non-malignant CNS: Table 1: WHO Grades for Select CNS Neoplasms has been replaced by a link to the most current CAP Protocol for CNS.
- Updated list of ambiguous terms that can be used for determining histology
- Breast rules M10 and H28 deleted

[See the Revision History](#) for a comprehensive description of changes.

2

2

Chchchch... Changes...


Moved to
Purpose &
Structure of
STR

- Solid Tumor Rules has been overhauled
 - Update Histology Tables
 - “Coding Histology” Section
 - Removed:
 - How to navigate the STR
 - How to use the STR
 - How to use equivalent terms/definitions
 - Ambiguous Terms
 - Site-Specific updates

3

3

Purpose and Structure of the STR



• Purpose:

- Determine multiple primaries
- Code histology

• Structure:

- Consists of 10 site-groups
 - Breast, lung, kidney, H&N, urinary, malignant CNS, non-malignant CNS, colon, melanoma
 - Other – all other sites

4

4

Histology Tables

Breast Site-group Instructions
C500-C506, C508-C509
(Excludes lymphoma and leukemia M9550 – M9593 and Kaposi sarcoma M9140)
Table 3: Specific Histologies, NOS/NST, and Subtype/Variants

Specific or NOS Term, Code, and Synonym(s)	Subtype(s)/Variant(s) and Synonym(s)
Acinic cell carcinoma 8550 • Acinar adenocarcinoma • Acinar carcinoma	
Adenoid cystic carcinoma 8200 • Adenocystic basal cell carcinoma • Carcinoma adenoides cysticum • Cylindromatous carcinoma	
Adenomyoepithelioma with carcinoma 8983 • AME • Malignant AME	Epithelial-myoepithelial carcinoma 8562
Apocrine carcinoma 8401.1	
Carcinoma NST 8500 • Carcinoma NOS • Carcinoma of no special type • Carcinoma NST with choriocarcinomatous features • Carcinoma NST with cribriform features • Carcinoma NST with melanotic features • Carcinoma NST with neuroendocrine features	Carcinoma with osteoclastic-like stromal giant cells 8035 Cribriform carcinoma 8201 (73) • Ductal carcinoma, cribriform type (73) • Cribriform carcinoma in situ (73) Pleomorphic carcinoma 8022 (73) Solid carcinoma 8230 (73) • Solid adenocarcinoma (73)

Head and Neck Site-group Instructions
C000-C148, C300-C330, C410, C411, C470, C754, C755
(Excludes lymphoma and leukemia M9550 – M9593 and Kaposi sarcoma M9140)
Table 2: Tumors of Nasal Cavity, Paranasal Sinuses and Skull Base

Specific or NOS Term, Code, and Synonym(s)	Subtype(s)/Variant(s) and Synonym(s)
Sarcoma 8800 (73)	Angiosarcoma 9120 (73) • Hemangiosarcoma Biphenotypic sinonasal sarcoma 9045 (73) • BNAS • Low grade sinonasal sarcoma with neural and myogenic features Epithelioid hemangioendothelioma 9133 (73) Fibrosarcoma 8810 (73) • Adult type fibrosarcoma Leiomyosarcoma 8890 (73) Malignant hemangioendothelioma 9130 (73) Rhabdomyosarcoma 8900 (73) • Alveolar rhabdomyosarcoma 8920 (73) • Embryonal rhabdomyosarcoma 8910 (73) • Pleomorphic rhabdomyosarcoma, adult type 8901 (73) • Spindle cell rhabdomyosarcoma 8912 (73) Synovial sarcoma 9040 (73) • Synovial cell sarcoma Undifferentiated pleomorphic sarcoma 8802 (73) • Malignant fibrous histiocytoma

- Specific Histologies, NOS/NST and Subtype/Variants Table
 - Column 1**
 - Contains specific and NOS histology terms
 - Specific don't have subtype/variant
 - NOS have subtype/variant
 - Synonyms are indented under the specific or NOS term
 - Column 2**
 - Contains subtype/variant of the NOS histology in column 1
 - Synonyms are indented under the term
 - No histology codes are given to the synonyms
 - Subtype/variant of the S/V in column 2
 - Indented under with a histology code assigned

5

5

Histology Rules: Coding Histology Section

- Ambiguous Terminology**
 - Removed examples from Ambiguous Terminology 3b
 - There is a NOS histology and a more specific (S/V) described by ambiguous terminology
 - Specific histology is clinically confirmed by a physician **OR**
 - Patient is receiving treatment based on the specific histology described by ambiguous terminology
 - If criteria not met, then code NOS histology
- ADDED:**
 - See Ambiguous Terms section in the General Instructions

6

6

General Instructions: Ambiguous Terms

- These instructions apply to coding histology
 - **NOT** to be used to determine reportability or assigning stage
- Within each site-group, the *Coding Histology* section will contain instructions for using *Ambiguous Terms* to assign a more specific histology

List of Ambiguous Terms		
Appears	Cannot rule out	Likely
Favor(s)	Presumed	Suspicious (for)
Suggestive of		

7

7

General Instructions: Ambiguous Terms

- These terms were previously included as ambiguous terms for coding histology
- Now they are considered **definitive terms** for a histologic subtype
 - A definitive term does **NOT** require a clinical verification of the S/V
 - This changes applies to **ALL** years covered by the STR
 - Previously abstracted cases do not need to be reviewed or updated



List of Definitive Terms		
Comparable with	Compatible with	Consistent with
Most likely	Probable	Typical (of)

8

8

General Instructions: Ambiguous Terms

- Code the specific histology described by ambiguous terminology **ONLY** when A or B is true:
 - A. The only diagnosis available is one histology term described by ambiguous term
 - B. There is a NOS histology and a more specific (s/v) described by ambiguous term
 - Specific histology is clinically confirmed by a physician **OR**
 - Patient is receiving treatment based on the specific histology described by ambiguous term
- If the specific histology doesn't meet the criteria, then code the NOS histology

9

9

Site-Group Updates


Breast
Lung
CNS
Urinary

10

10

Breast


- **Multiple Primary Rules:** Multiple Tumors are
 - **M10** – Single Primary
 - Multiple tumors of ductal and lobular
- **Histology Rules:** Multiple Tumors are extracted as a Single Primary
 - **H28** – Code 8522
 - Carcinoma NST and multiple tumors



11

11

Breast

- **M5** – Multiple Primaries
 - Subsequent tumor after being clinically disease-free for greater than 5 years
 - *Note 2:* Clinically disease-free means there was no evidence of recurrence on follow-up
- 
 - Mammogram WNL
 - Scans are WNL

12

12

Breast – Coding Histology

- **Note:** Only code **differentiation** or **features** when there is a **specific code** for the NOS with differentiation **OR** the NOS with features in *Table 2* or *Table 3* or the ICD-O updates
 - *Example:*
 - **Do not** code **apocrine carcinoma** when the diagnosis specifies apocrine differentiation or features.
 - Apocrine differentiation is frequently present in:
 - Carcinoma NST/duct carcinoma
 - Subtype/variants of carcinoma NST/duct carcinoma
 - Lobular carcinoma NOS
 - Pleomorphic LCIS

13

13

Breast – Table 2: Histology Combination Codes

Breast Site-group Instructions
C500-C506, C508-C509
(Excludes lymphoma and leukemia M9590 – M9993 and Kaposi sarcoma M9140)

Table 2: Histology Combination Codes

Required Histology Terms	Histology Combination Term and Code
DCIS/duct carcinoma/carcinoma NST 8500 OR any subtype/variant of carcinoma NST (see Table 3)	Duct and lobular 8522 ^{1 2} <ul style="list-style-type: none">• Invasive duct and in situ lobular (/3)³• DCIS and invasive lobular (/3)• Invasive duct and invasive lobular (/3)• Invasive carcinoma with ductal and lobular features ("mixed type carcinoma") (/3)⁴
AND	
LCIS/lobular carcinoma (8520) OR pleomorphic lobular carcinoma in situ 8519/2	<ul style="list-style-type: none">• DCIS and LCIS (/2)³

¹ 8522 is used when:

- Duct and lobular carcinoma are present in a single tumor **OR**
- All tumors in the same breast are mixed duct and lobular

² **Do not** use when the diagnosis is carcinoma NST/duct carcinoma with lobular **differentiation**.

³ Includes pleomorphic LCIS

⁴ CAP uses the term invasive carcinoma with ductal and lobular features ("mixed type carcinoma") to indicate both duct and lobular are present. This is an exception to the instruction that features are not coded.

14

14

Lung – Coding Histology

- **Instruction 4 – DO NOT CODE** histology described as:

- Architecture
- Foci; focus; focal
- Pattern – **exceptions** below
 - Acinar pattern: Adenocarcinoma, acinar predominant **8551**
 - Lepidic (growth) pattern: Adenocarcinoma, lepidic predominant **8250**
 - Micropapillary pattern: Adenocarcinoma, micropapillary predominant **8265**
 - Papillary pattern: Adenocarcinoma, papillary predominant **8260**
 - Solid pattern: Adenocarcinoma, solid predominant **8230**



15

15

Lung

- **Histology Rules: Single Tumor**

- **H4** – Code the histology when only one histology is present



- **Note 5**: Single histologies identified as **pattern** should be coded
- **H7** – Code the histology that comprises the greatest percentage of tumor

- **Note 3**: CAP allow pathologists to identify bulleted histologies as **pattern** along with percentages; the histology pattern with the greatest percentage can be coded.

16

16

Non-Malignant CNS – Behavior Code


- Behavior determines which set of CNS rules should be used:
 - Malignant **or**
 - Non-malignant
- **Priority Order for Using Documentation to Assign Behavior**
 1. **Pathology:** Tissue from resection in the following order:
 - A. Use the pathologist's description of behavior
 - B. Cases are reportable as **non-malignant** when pathology states **WHO Grade 1**
 - i. **WHO Grade 2** may be either malignant or non-malignant
 - Use the pathologist's description of behavior first
 - If not available, code corresponding histology code and behavior list in ICD-O, ICD-O updates, or STR

17

17

Non-Malignant CNS – WHO Grades

- **Note 3** (Updated)
 - WHO **does not** provide Grade for **all** CNS and peripheral nerve neoplasms



WHO Grade Definitions

WHO Grade	Definition
WHO Grade I	Non-malignant (/0 or /1)
WHO Grade II	Malignant or Non-malignant
WHO Grade III	Malignant (/3) (See Malignant CNS site-group)
WHO Grade IV	Malignant (/3) (See Malignant CNS site-group)

18

18

Malignant and Non-Malignant CNS – Table 1

Malignant CNS and Peripheral Nerves Equivalent Terms and Definitions
C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753
Lymphoma and leukemia M9590 – M9993 and Kaposi sarcoma

Table 1: WHO Grades for Select CNS Neoplasms

Histology	WHO Grade
Atypical meningioma	2
Atypical teratoid/rhabdoid tumor	4
Central neurocytoma	2
Cerebellar liponeurocytoma	2
Chordoid glioma of third ventricle	2
Choroid plexus carcinoma	3
Choroid plexus papilloma	2
CNS embryonal tumor	4
CNS embryonal tumor with rhabdoid features	4
Craniopharyngioma	1

WHO Grades for Select CNS Neoplasms

- **Note 4:** Refer to the **CNS CAP Protocol** to **code behavior based on WHO grade for specific histologies** when grade is not available

19

19

Malignant CNS

• Behavior Code

• Priority Order for Using Documentation to Assign Behavior

- 1B. Cases are reported as malignant when pathology states WHO Grade 3 or 4
 - i. **WHO Grade 2** may be either non-malignant or malignant
 - Use the pathologist's description of behavior first.
 - When not available and the CNS tumor is stated to be WHO Grade 2, code the corresponding ICD-O histology code and behavior listed in ICD-O, ICD-O updates, or STR
 - Code the WHO Grade in the appropriate SSDI field
 - *Example:* Astrocytoma, IDH-mutant NOS, Grade 2 – code 9400/3


 Update

20

20

Non-Malignant CNS –Histology Table 5

Table 5: Specific Histologies, NOS, and Subtypes/Variants

Specific or NOS Term, Code, and Synonym(s)	Subtype(s)/Variant(s) and Synonym(s)
Optic glioma 9421 (/1) <ul style="list-style-type: none">Pilocytic astrocytoma	
Papillary glioneuronal tumor 9509 (/1) * <ul style="list-style-type: none">Diffuse leptomeningeal glioneuronal tumor *Rosette-forming glioneuronal tumor	
Paraganglioma 8693 (/1) 10	
Perineurioma 9571 (/0)	
Pineocytoma 9361 (/1)	
Pituitary adenoma NOS 8272 (/0) 11	
<ul style="list-style-type: none">CorticotrophGonadotroph adenomaNull cell adenomaPlurihormonal and double adenomasSomatotroph adenomaThyrotroph adenoma	

11 A diagnosis of pituitary adenoma NOS is coded 8272/0. A diagnosis of pituitary adenoma/PitNET (this is a single term) or PitNET is coded 8272/3.

21

21

Non-Malignant CNS – Histology Table 5

Table 5: Specific Histologies, NOS, and Subtypes/Variants

Specific or NOS Term, Code, and Synonym(s)	Subtype(s)/Variant(s) and Synonym(s)
Polymorphous low-grade neuroepithelial tumor of the young 9413 (/0) 12 <ul style="list-style-type: none">PLNTV	
Prolactinoma 8271 (/0)	
Rhabdomyoma 8900 (/0)	
Schwannoma 9560 (/0) <ul style="list-style-type: none">Acoustic neuromaCellular schwannomaNeurileiomaNeurinomaPlexiform schwannoma	Melanotic schwannoma 9560 (/1)
Solitary fibrous tumor Grade 1 8815 (/1) 13 <ul style="list-style-type: none">Hemangiopericytoma Grade 1Hemangiopericytoma Grade 2Solitary fibrous tumor	
Spindle cell oncocytoma 8290 (/0)	
Subependymal giant cell astrocytoma 9384 (/1)	

13 Behavior for solitary fibrous tumor, grade I changed from /0 to /1 effective with cases diagnosed 1/1/2025 forward. The change is per Cancer PathCHART expert neuropathologist review.

22

22

Non-Malignant CNS

- **Multiple Primary Rules – Multiple Tumors module**
 - **M8 – Multiple primaries**
 - When multiple tumors are present in any of the following sites:
 - **UPDATE** to this bullet:
 - Meninges of cranial nerves **C700** and any other part of the CNS

23

23

Malignant CNS – Histology Table 2

Table 2: Specific Histologies, NOS, and Subtypes/Variants

Specific or NOS Term, Code, and Synonym(s)	Subtype(s)/Variant(s) and Synonym(s)
Anaplastic ganglioglioma 9505	
Astroblastoma 9430 <ul style="list-style-type: none"> • Astroblastoma, MN1-altered 	
Astrocytoma NOS 9400 ¹ <ul style="list-style-type: none"> • Astrocytoma, IDH-mutant, grade 2 • Diffuse astrocytoma IDH-mutant • Diffuse astrocytoma IDH-wildtype • Diffuse astrocytoma NOS 	Anaplastic astrocytoma IDH-mutant 9401 <ul style="list-style-type: none"> • Anaplastic astrocytoma IDH-wildtype • Anaplastic astrocytoma NOS Astrocytoma, IDH-mutant, grade 3 9401 Astrocytoma, IDH-mutant, grade 4 9445 Gemistocytic astrocytoma IDH-mutant 9411 Pleomorphic xanthroastrocytoma 9424 <ul style="list-style-type: none"> • Anaplastic pleomorphic xanthroastrocytoma

Added

¹ Pathologists may use the terms glioma and astrocytoma interchangeably. These terms are equal/equivalent only when they are used to describe a synonym of astrocytoma or subtype/variant of astrocytoma. The terms glioma NOS and astrocytoma NOS are not equal/equivalent terms.

24

24

Malignant CNS – Histology Table 2

Table 2: Specific Histologies, NOS, and Subtypes/Variants

Specific or NOS Term, Code, and Synonym(s)	Subtype(s)/Variant(s) and Synonym(s)
Oligodendroglioma NOS 9450⁹ <ul style="list-style-type: none"> Oligodendroglioma 1p/19q-codeleted Oligodendroglioma IDH-mutant Oligodendroglioma IDH-mutant and 1p/19q-codeleted, grade 2 	Anaplastic oligodendroglioma NOS 9451 <ul style="list-style-type: none"> Anaplastic oligodendroglioma, IDH-mutant 1p/19q-codeleted Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3
Peripheral primitive neuroectodermal tumor 9364 <ul style="list-style-type: none"> Ewing sarcoma pPNET 	
Pilocytic astrocytoma 9421^{10 11}	Pilomyxoid astrocytoma 9425
Pineal parenchymal tumor of intermediate differentiation 9362 <ul style="list-style-type: none"> Pineoblastoma 	Papillary tumor of the pineal region 9395
Pituitary adenoma/pituitary neuroendocrine tumor 8272 (/3)¹² <ul style="list-style-type: none"> PitNET Pituitary adenoma/PitNET 	

Added

• Diffuse low-grade glioma, MAPK pathway- altered+

¹² A diagnosis of pituitary adenoma NOS is coded 8272/0. A diagnosis of pituitary adenoma/PitNET (this is a single term) or PitNET is coded 8272/3.

25

25

Malignant CNS – Histology Table 2

Table 2: Specific Histologies, NOS, and Subtypes/Variants

Specific or NOS Term, Code, and Synonym(s)	Subtype(s)/Variant(s) and Synonym(s)
Sarcoma NOS 8800 <div> <p>Cases diagnosed 1/1/25 forward – chondrosarcoma is no longer valid for Malignant CNS</p> </div>	Angiosarcoma 9120 Chondrosarcoma 9220¹³ <ul style="list-style-type: none"> Mesenchymal chondrosarcoma 9240 Leiomyosarcoma 8890 <ul style="list-style-type: none"> Granular cell leiomyosarcoma Inflammatory leiomyosarcoma Epithelioid leiomyosarcoma 8891 Myxoid leiomyosarcoma 8896 Myxoid pleomorphic liposarcoma 8859 Osteosarcoma 9180 Primary intracranial sarcoma, DICER1-mutant 9480 Round cell sarcoma with EWSR1-non-ETS fusion 9366 Sarcoma with BCOR genetic alterations 9268 Undifferentiated pleomorphic sarcoma 8802 <ul style="list-style-type: none"> Malignant fibrous histiocytoma

26

26

Urinary – Multiple Primary Rules

- **M9 – Single Primary**
 - Multiple invasive urothelial cell carcinoma in the bladder
 - All tumors are:
 - Urothelial or Urothelial S/V (*except* micropapillary)
 - Micropapillary
 - Timing irrelevant
 - An occurrence of micropapillary and an occurrence of urothelial carcinoma would be **multiple primaries** (See Rule **M8**)
- **M11 – Single Primary**
 - Urothelial carcinomas in multiple urinary organs (Renal pelvis, Bladder, Ureter, Urethra)
 - All tumors are:
 - Urothelial or urothelial S/V (*except* micropapillary)
 - Micropapillary
 - Do **NOT** apply to other histologies
 - Applies to tumors **occur less than 3yrs apart**
 - Behavior irrelevant

27

27

Urinary – Histology Rules

- **Single Tumor** module – **H3**
- **Multiple Tumors Abstracted as a Single Primary** module – **H9**
 - **Code the S/V** when all multifocal/multicentric tumors are a NOS and a **SINGLE S/V** of that NOS
 - **DELETED:**
 - Papillary urothelial carcinoma 8130 and a S/V of papillary urothelial carcinoma
 - This is no longer applicable for these two histology rules

28

28

29

Reminders...

Use

- Use the most current STR as soon as it is released

Download

- **DOWNLOAD** the manual

Review

- Review the entire change log
- <https://seer.cancer.gov/tools/solidtumor/revisions.html>

Complete the Quiz

- ***After watching all annual update training videos take the 2026 quiz***

29

Questions? Contact me.

Melissa Riddle, ODS-C
Education/Training
Iowa Cancer Registry
melissa-riddle@uiowa.edu



30

30